Fund Overlap
See which holdings any two equity ETFs have in common, along with top differences in exposure.
For overlap across multiple ETFs use Portfolio Builder
11
Number of overlapping holdings
23.9%
% of IDNA's 51 holdings also in CANC
22.9%
% of CANC's 48 holdings also in IDNA
Overlap by Weight
Sector Drift (IDNA minus CANC)
Overlapping Holdings
Top 5 only shown here. Please log-in or sign up for a Basic (Free) membership to view the complete list.
| Company | Weight in IDNA |
Weight in CANC |
Overlap | |
|---|---|---|---|---|
 |
ASTRAZENECA PLC | 5.1% | 4.3% | 4.3% |
 |
EXELIXIS INC | 4.9% | 4.0% | 4.0% |
|
REVOLUTION MEDICINES, INC. | 3.7% | 5.4% | 3.7% |
|
ARCELLX, INC. | 3.8% | 3.0% | 3.0% |
|
MERCK & CO. INC. | 4.1% | 2.9% | 2.9% |
Position Highlights (Non-Overlapping Exposures)
IDNA Overweight Relative to CANC
 |
BEIGENE, LTD. | 6.2% |
 |
ROCHE HOLDING LTD | 5.5% |
 |
SANOFI-AVENTIS | 5.4% |
|
GSK PLC | 5.3% |
|
SPRINGWORKS THERAPEUTICS, INC. | 5.0% |
 |
TAKEDA PHARMACEUTICAL CO LTD | 4.9% |
 |
GENMAB A/S | 4.3% |
 |
BIONTECH SE SPONSORED ADR | 3.7% |
|
TWIST BIOSCIENCE CORP. | 3.6% |
|
MODERNA, INC. | 3.3% |
IDNA Underweight Relative to CANC
|
ELI LILLY & CO | -5.3% |
|
ROCHE HOLDINGS LTD-SPONS ADR | -5.2% |
|
BRISTOL-MYERS SQUIBB CO | -4.5% |
|
NOVARTIS AG | -4.2% |
|
BRIDGEBIO PHARMA, INC. | -4.1% |
|
NUVALENT, INC. CLASS A | -3.8% |
|
ZAI LAB LTD. UNSPONSORED ADR | -3.7% |
|
GENMAB A/S SPONSORED ADR | -3.1% |
 |
MERUS N.V. | -3.1% |
|
SUMMIT THERAPEUTICS INC | -3.1% |